Exelixis Initiates P-III COSMIC-313 Study of Triple Combination Therapy for Advanced Renal Cell Carcinoma
Shots:
- The P-III COSMIC-313 study involves assessing of Cabometyx (cabozantinib) + Opdivo (nivolumab) + Yervoy (ipilimumab) vs nivolumab+ ipilimumab + PBO in 676 patients in the ratio (1:1) with previously untreated advanced RCC across 150 sites globally
- The P-III COSMIC-313 study follows ongoing P-Ib study assessing cabozantinib + nivolumab with/without ipilimumab in patients with advanced genitourinary cancers including RCC- previously treated with sorafenib
- Cabometyx is a tyrosine kinase inhibitor promoting an immune-permissive environment in combination with immune checkpoint inhibitors and is approved in the US for HCC & advanced RCC. Opdivo & Yervoy are checkpoint inhibitors developed by BMS
Ref: Exelixis | Image: Brand Navigation
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com